Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia

@article{Lafeuille2014SystematicRO,
  title={Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia},
  author={M Lafeuille and Jason Dean and Val{\'e}rie Carter and Mei Sheng Duh and John Fastenau and Riad D Dirani and Patrick Lefebvre},
  journal={Current Medical Research and Opinion},
  year={2014},
  volume={30},
  pages={1643 - 1655}
}
Abstract Objective: To assess the impact of long-acting injectables (LAIs) versus oral antipsychotics (OAs) on hospitalizations among patients with schizophrenia by conducting a systematic literature review of studies with different study designs and performing a meta-analysis. Methods: Using the PubMed database and major psychiatric conference proceedings, a systematic literature review for January 2000 to July 2013 was performed to identify English-language studies evaluating schizophrenia… 
The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis.
TLDR
The overall results suggest that LAIs are at least comparable to orals in supporting important healthcare outcomes for those with schizophrenia, and support clinical practice in encouraging providers to prescribe LAIs when indicated.
A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal
TLDR
To put LAI–oral comparisons into clinical context, the following information is urgently necessary: how LAIs compare with each other in head-to-head comparisons, and how effective is clozapine when LAIs are ineffective.
Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis
TLDR
Based on multiple studies with varying sub-types of patient populations with schizophrenia in the United States published in the last decade, this meta-analysis demonstrated that LAI antipsychotics were associated with improved medication adherence and significant clinical benefit such as reduced hospitalizations and ER admissions compared with OA.
Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis
  • Seon-Cheol Park, M. Choi, Seung-Hwan Lee
  • Psychology, Medicine
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2018
TLDR
There is moderate to high level of evidence suggesting that in the treatment of schizophrenia, LAI SGAs have higher efficacy and are associated with higher rates of extrapyramidal syndrome and prolactin-related symptoms.
Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis
TLDR
Long-acting injectable antipsychotic drugs were associated with better adherence compared with oral antipsychotics in patients with early psychosis, and the number of times a psychiatric acute care service was used.
Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany
TLDR
Aripiprazole-depot treatment for schizophrenia patients has major potential in terms of cost savings for the German statutory health insurance and is suggested to be the more cost-effective strategy.
Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis.
TLDR
Early prescription of LAI-AP seems beneficial in FEP with poor prognostic factors, and clinical and functional improvements were observed.
Hospitalizations and emergency room visits after initiation of long-acting injectable antipsychotics
TLDR
This retrospective study suggests that the initiation of LAIs is associated with a reduced rate of psychiatric hospitalizations as well as a reduction in the 1-year rate of hospitalizations and ER visits for those patients who receive injections on a regular basis.
Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis
TLDR
Patients with poor prognosis in the early stage of their disease seem to benefit from early prescription of LAI-AP which can reduce and delay relapses and rehospitalizations, which is particularly relevant to avoid functional deterioration.
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
TLDR
The main aims of this review are to summarize the existing data on the efficacy and tolerability of LAIAs compared with oral formulations in the management of schizophrenia and related disorders, and to analyze the barriers that exist to the more widespread use of these formulations.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
TLDR
Results from mirror-image studies in patients eligible for clinical use of LAI showed strong superiority of LAIs compared to oral antipsychotics in preventing hospitalization, in contrast to the recent meta-analysis of RCTs, which showed no superiority.
Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
TLDR
The comparative effectiveness of antipsychotic formulations is sensitive to research design, and depot formulations displayed significant advantages in nonrandomized observational studies, whereas in RCTs no difference was observed.
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
TLDR
In RCTs, which are less representative of real-world patients than naturalistic studies, pooled LAIs did not reduce relapse compared with OAPs in schizophrenia patients, and studies comparing FGA-LAIs vs second-generation antipsychotics-LAI and LAI vs OAP R CTs in real- world patients are needed.
The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia
TLDR
Atypical long- acting (especially risperidone)/extended-release antipsychotic medication is likely to be a cost-effective, first-line strategy for managing schizophrenia, compared with long-acting haloperidol and other oral or depot formulations, irrespective of country-specific differences.
Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada
TLDR
There was no apparent difference in treatment discontinuation or hospitalization between RLAI and FGAI treated patients, although analysis was compromised by low patient numbers and decreased EPS with R LAI may offer a significant clinical benefit to patients with schizophrenia.
Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials
TLDR
The present meta-analysis shows superior efficacy for the SGLAI over placebo on psychotic symptoms, although with a relatively small effect size; no evidence of superiority in efficacy over oral antipsychotics; and modest evidence of greater symptoms of extrapyramidal side effects.
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden
TLDR
A naturalistic mirror-image study found that switching to long-acting injectable risperidone led to sizeable reductions in inpatient resource use, which coincide with the findings of other international studies.
Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia
TLDR
By virtue of its periodic intramuscular administration, RLAI offers the efficacy and tolerability of an atypical medication without the compliance issues associated with oral drugs, and leads to significant decreases in hospitalisation.
A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia
TLDR
Consistent with prior clinical trial research, treatment-adherent schizophrenia patients who were treated in usual care with olanzapine had a lower risk of psychiatric hospitalization than risperidone-treated patients, and lower hospitalization costs appear to more than offset the higher medication acquisition cost of olanZapine.
...
1
2
3
4
5
...